Search
Tapinarof
go.drugbank.com/drugs/DB06083ApprovedInvestigational[L41845, A248790] Tapiranof was first discovered as a metabolite (3,5-dihydroxy-4-isopropylstilbene) produced in _Photorhabdus luminescens_, a gram-negative bacillus that lives symbiotically with the _ … It is available as a topical cream to be applied to the affected area once daily.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesSynonyms: 3,5-Dihydroxy-4-isopropyl-trans-stilbeneCenobamate
go.drugbank.com/drugs/DB06119ApprovedInvestigational[A188442,L10653] The exact mechanism of action has not been described in the literature, though it positively modulates GABA<sub>A</sub> and inhibits voltage gated sodium channels.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 InducersSUVN-502
go.drugbank.com/drugs/DB06140InvestigationalSUVN-502 is a novel, potent, safe, highly selective and orally active antagonist at a central nervous system serotonin receptor site 5-HT6 intended for treatment of cognitive disorders such as Alzheimer
Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingSulfadimethoxine
go.drugbank.com/drugs/DB06150ApprovedVet approvedWithdrawnIt is widely available in Russia as an over-the-counter drug manufactured by a number of Russian pharmaceutical companies. … Sulfadimethoxine is a sulfonamide antibiotic. Sulfadimethoxine is used to treat many infections, including treatment of respiratory, urinary tract, enteric, and soft tissue infections.
Mixtures: TP-SULTRIME 80/400MG/G POWDERCategories: Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 Enzyme InhibitorsForodesine
go.drugbank.com/drugs/DB06185Investigationalleukemia and cutaneous T-cell lymphoma. … Forodesine is a highly potent, orally active, rationally designed PNP inhibitor that has shown activity in preclinical studies with malignant cells and clinical utility against T-cell acute lymphoblastic
Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingSynonyms: 1,4-Dideoxy-4-aza-1-(S)-(9-deazahypoxanthin-9-yl)-D-ribitol, (1S)-1,4-dideoxy-4-imino-(9-deazahypoxanthin-9-yl)-D-ribitolAtrasentan
go.drugbank.com/drugs/DB06199ApprovedInvestigationalAtrasentan is a novel, selective endothelin A receptor antagonist (SERA). … [L52855] In April 2025, atrasentan was granted accelerated approval by the FDA for the reduction of proteinuria in patients with primary IgA nephropathy, becoming the first endothelin A receptor antagonist
Categories: Cytochrome P-450 CYP2B6 Inducers, P-glycoprotein inhibitorsAlogliptin
go.drugbank.com/drugs/DB06203ApprovedInvestigationalAlogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). … Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer.
Mixtures: INCRESINA PCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesTapentadol
go.drugbank.com/drugs/DB06204ApprovedInvestigationalTapentadol is a centrally-acting synthetic analgesic with a dual mechanism of action. It is a mu-opioid receptor agonist that also inhibits norepinephrine reuptake.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesSynonyms: 3-[(1R,2R)-3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol, PHENOL, 3-((1R,2R)-3-(DIMETHYLAMINO)-1-ETHYL-2-METHYLPROPYL)-Eltrombopag
go.drugbank.com/drugs/DB06210ApprovedInvestigationalITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood. … Eltrombopag has also been recently approved (late 2012) for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesProducts: REVOLADE® TABLETAS 25 MG, REVOLADE ® TABLETAS 50 MG